The Medicines Company

+$0.00 (+0.0%)
Closing price January 6, 2020
With insiders buying shares at these lofty levels of the market, it’s a good bet they are very positive on their companies going forward. That's a bullish sign for stock investors as we wrap up...
Solid insider buying into the teeth of one of the biggest rallies in years is a very bullish sign. Insiders would not be willing to risk capital at this level if they were not very bullish on the...
RBC thinks investors can buy these biotech stocks now, because the timing in their view is irrelevant, and they see the stocks de-risked and having mergers and acquisitions potential.
Jefferies highlights top growth stocks to buy each week, and this week is no exception. These four all make good sense now and have outstanding upside potential.
24/7 Wall St. has collected several big FDA decisions and mid- to late-stage trials that should be coming up in November and December.
Now is the time to look for good growth stocks as the second half of the year could have solid upside after a flat first half.
With second-quarter earnings right around the corner, you can bet many of the corporate executives and 10% owners are looking to add shares before trading windows close.
This past week started to resemble just what we have been expecting the rest of the summer to look like: volatile. Yet, big-time insiders were big-time buyers.
In a recent research note, Jefferies analysts focus on some growth stocks to buy that could have some solid upside from current levels, and that also are not part of the overly crowded trade club.
Jefferies believes most of the significant biotech downside already occurred, though volatility could continue in the near term.
Jefferies has four top biotech picks for 2016 that all have substantial upside and may provide investors with solid alpha for 2016.
These companies are well along in clinical trials and some are close to presenting Phase 3 results. Sticking with industry leaders always makes sense in a very volatile sector.
A new RBC report focuses on top biotech stocks with key data readouts coming in 2016. These three seem to be the farthest along and offer the best chance for approval.
Jefferies analysts have zeroed in on some top growth stocks to buy that are not part of over-crowded trades or momentum hype.
Alnylam Pharmaceuticals and The Medicines Company made waves Monday morning despite downward pressure from the broad markets.